Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Trial Details

NCT ID

NCT06924606

Phase

PHASE2

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• JS207 injection +docetaxel
• JS207 injection +JS004 injection
• JS207 injection

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Jilin City, Changchun, China|43.84652,126.5608
• Hunan, Changsha, China|32.92741,120.18021
• Sichuan, Chengdu, China|35.1221,105.48032
• Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

• Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical radiochemothe…
• Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combin…
• Subjects must have at least one measurable lesion according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.